Autologous T-cell antigen coupler targeting HER2 (TAC01-HER2) in advanced or metastatic solid tumors.
Ann OncolMay 22, 2026 (epub)
Clinical ResearchOncology (Medical)
E E Dumbrava, D Olson, M A Gouda et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase I clinical trial evaluated TAC01-HER2, an autologous T-cell product targeting HER2, in 23 patients with HER2-positive advanced solid tumors. The study found that TAC01-HER2 was safe and well-tolerated, with a disease control rate of 61.1% among evaluable patients and a median progression-free survival of 2.6 months.
Key findings
- Cytokine release syndrome occurred in 60.9% of patients, with no treatment-related deaths reported.
- The disease control rate was 61.1% in 18 patients with evaluable tumors.
- The median progression-free survival was 2.6 months, with an overall survival rate of 57.9% at 6 months.
Why it matters
The study highlights a novel approach to T-cell therapy that may provide a safer alternative to traditional CAR T-cell therapies, particularly for patients with HER2-positive tumors who have limited treatment options.